Treatment strategy for POEMS syndrome

Nobutoshi Kawamura, Jun Ichi Kira

研究成果: ジャーナルへの寄稿評論記事

抄録

POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes) is a paraneoplastic disease associated with an underlying plasma cell dyscrasia. This syndrome usually progresses slowly and can be life-threatening. No large-scale controlled study providing convincing evidence for the treatment of this rare condition has thus for been conducted. However, several lines of evidence have shown the efficacy of conventional therapies such as radiation, alkylator-based treatment, and corticosteroid therapy. Recent studies have also proposed novel therapeutic strategies such as autologous peripheral blood stem cell transplantation (auto-PBSCT) and thalidomide, lenalidomide, and bevacizumab therapies. We reviewed the current treatment strategies for POEMS syndrome and summarized them as follows; 1) Radiotherapy or surgical resection is highly effective for isolated plasmacytoma. 2) Melphalan-predonisolone administration may be a treatment option for the patients with widespread bone lesions. 3) High dose chemotherapy with auto-PBSCT is a promising novel approach that can lead to dramatic improvement particularly in patients with good systemic condition. 4) Plasma exchange and immunoglobulin treatment are not recommended. 5) Administration of thalidomide and lenalidomide may ameliorate the clinical conditions of the patients who are unable to undergo auto-PBSCT; however, this needs further confirmation. Finally, we emphasized that the efficacy of these therapies largely depends on the appropriate early diagnosis of POEMS syndrome.

元の言語英語
ページ(範囲)621-626
ページ数6
ジャーナルBrain and Nerve
60
発行部数6
出版物ステータス出版済み - 6 1 2008

Fingerprint

POEMS Syndrome
Peripheral Blood Stem Cell Transplantation
Therapeutics
Thalidomide
Paraproteinemias
Plasma Exchange
Melphalan
Plasmacytoma
Alkylating Agents
Immunoglobulins
Early Diagnosis
Adrenal Cortex Hormones
Radiotherapy

All Science Journal Classification (ASJC) codes

  • Clinical Neurology

これを引用

Treatment strategy for POEMS syndrome. / Kawamura, Nobutoshi; Kira, Jun Ichi.

:: Brain and Nerve, 巻 60, 番号 6, 01.06.2008, p. 621-626.

研究成果: ジャーナルへの寄稿評論記事

Kawamura, N & Kira, JI 2008, 'Treatment strategy for POEMS syndrome', Brain and Nerve, 巻. 60, 番号 6, pp. 621-626.
Kawamura, Nobutoshi ; Kira, Jun Ichi. / Treatment strategy for POEMS syndrome. :: Brain and Nerve. 2008 ; 巻 60, 番号 6. pp. 621-626.
@article{3beaff237fee4d439bb02b52a450aa83,
title = "Treatment strategy for POEMS syndrome",
abstract = "POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes) is a paraneoplastic disease associated with an underlying plasma cell dyscrasia. This syndrome usually progresses slowly and can be life-threatening. No large-scale controlled study providing convincing evidence for the treatment of this rare condition has thus for been conducted. However, several lines of evidence have shown the efficacy of conventional therapies such as radiation, alkylator-based treatment, and corticosteroid therapy. Recent studies have also proposed novel therapeutic strategies such as autologous peripheral blood stem cell transplantation (auto-PBSCT) and thalidomide, lenalidomide, and bevacizumab therapies. We reviewed the current treatment strategies for POEMS syndrome and summarized them as follows; 1) Radiotherapy or surgical resection is highly effective for isolated plasmacytoma. 2) Melphalan-predonisolone administration may be a treatment option for the patients with widespread bone lesions. 3) High dose chemotherapy with auto-PBSCT is a promising novel approach that can lead to dramatic improvement particularly in patients with good systemic condition. 4) Plasma exchange and immunoglobulin treatment are not recommended. 5) Administration of thalidomide and lenalidomide may ameliorate the clinical conditions of the patients who are unable to undergo auto-PBSCT; however, this needs further confirmation. Finally, we emphasized that the efficacy of these therapies largely depends on the appropriate early diagnosis of POEMS syndrome.",
author = "Nobutoshi Kawamura and Kira, {Jun Ichi}",
year = "2008",
month = "6",
day = "1",
language = "English",
volume = "60",
pages = "621--626",
journal = "Brain and Nerve",
issn = "1881-6096",
publisher = "Igaku-Shoin Ltd",
number = "6",

}

TY - JOUR

T1 - Treatment strategy for POEMS syndrome

AU - Kawamura, Nobutoshi

AU - Kira, Jun Ichi

PY - 2008/6/1

Y1 - 2008/6/1

N2 - POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes) is a paraneoplastic disease associated with an underlying plasma cell dyscrasia. This syndrome usually progresses slowly and can be life-threatening. No large-scale controlled study providing convincing evidence for the treatment of this rare condition has thus for been conducted. However, several lines of evidence have shown the efficacy of conventional therapies such as radiation, alkylator-based treatment, and corticosteroid therapy. Recent studies have also proposed novel therapeutic strategies such as autologous peripheral blood stem cell transplantation (auto-PBSCT) and thalidomide, lenalidomide, and bevacizumab therapies. We reviewed the current treatment strategies for POEMS syndrome and summarized them as follows; 1) Radiotherapy or surgical resection is highly effective for isolated plasmacytoma. 2) Melphalan-predonisolone administration may be a treatment option for the patients with widespread bone lesions. 3) High dose chemotherapy with auto-PBSCT is a promising novel approach that can lead to dramatic improvement particularly in patients with good systemic condition. 4) Plasma exchange and immunoglobulin treatment are not recommended. 5) Administration of thalidomide and lenalidomide may ameliorate the clinical conditions of the patients who are unable to undergo auto-PBSCT; however, this needs further confirmation. Finally, we emphasized that the efficacy of these therapies largely depends on the appropriate early diagnosis of POEMS syndrome.

AB - POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes) is a paraneoplastic disease associated with an underlying plasma cell dyscrasia. This syndrome usually progresses slowly and can be life-threatening. No large-scale controlled study providing convincing evidence for the treatment of this rare condition has thus for been conducted. However, several lines of evidence have shown the efficacy of conventional therapies such as radiation, alkylator-based treatment, and corticosteroid therapy. Recent studies have also proposed novel therapeutic strategies such as autologous peripheral blood stem cell transplantation (auto-PBSCT) and thalidomide, lenalidomide, and bevacizumab therapies. We reviewed the current treatment strategies for POEMS syndrome and summarized them as follows; 1) Radiotherapy or surgical resection is highly effective for isolated plasmacytoma. 2) Melphalan-predonisolone administration may be a treatment option for the patients with widespread bone lesions. 3) High dose chemotherapy with auto-PBSCT is a promising novel approach that can lead to dramatic improvement particularly in patients with good systemic condition. 4) Plasma exchange and immunoglobulin treatment are not recommended. 5) Administration of thalidomide and lenalidomide may ameliorate the clinical conditions of the patients who are unable to undergo auto-PBSCT; however, this needs further confirmation. Finally, we emphasized that the efficacy of these therapies largely depends on the appropriate early diagnosis of POEMS syndrome.

UR - http://www.scopus.com/inward/record.url?scp=46049110690&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46049110690&partnerID=8YFLogxK

M3 - Review article

C2 - 18567357

AN - SCOPUS:46049110690

VL - 60

SP - 621

EP - 626

JO - Brain and Nerve

JF - Brain and Nerve

SN - 1881-6096

IS - 6

ER -